SecBot SecBot
6-K ·Filed Jul 30, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001104659-26-088458
Notable filing: 6-K
Actionable Insight ▲ Bullish

The SAFFRON and SANOVO Phase III readouts (savolitinib) in H2 2026 are the next major binary catalysts that could support global filings. Additionally, sovleplenib NDA decisions for ITP and wAIHA in China are pending. The company's strong cash position and growing China commercial franchise provide a solid floor, while the early-stage ATTC platform adds optionality. Monitor partner discussions for out-licensing of ATTC assets.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

HCM drug pipeline →

ORPATHYS

◆ Mixed Named in this 6-K
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.77
T+0 close · Jul 30, 2026 · via day close
Latest settled
+33.33%
T+60 · $14.36
Vs SPY
+30.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $10.77entry
  2. T+1 · 4mo ago +3.34%α +2.64% · $11.13
  3. T+5 · 3mo ago +9.84%α +6.22% · $11.83
  4. T+20 · 3mo ago +15.27%α +11.31% · $12.42
  5. T+60 · 25d ago +33.33%α +30.87% · $14.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED reported H1 2026 results with total revenue essentially flat at $278.3M (vs $277.7M in H1 2025) but a strong 23% increase in Oncology/Immunology marketed product revenue to $121.4M, driven by ELUNATE (+41%), SULANDA (+45%), and FRUZAQLA ex-US (+70%). Net income attributable to HUTCHMED was $15.9M, down sharply from $455.0M in H1 2025 which included a $416.3M gain on the SHPL divestment. The company reiterated full-year 2026 Oncology/Immunology revenue guidance of $330M-$450M and ended the period with $1.37B in cash. Key pipeline catalysts include expected SAFFRON and SANOVO Phase III readouts in H2 2026 and two sovleplenib NDAs under priority review in China.

Key Facts

  • Total revenue H1 2026: $278.3M (flat vs $277.7M H1 2025; -4% actual, +4% CER)
  • Oncology/Immunology consolidated revenue: $162.3M, up 13% (10% CER)
  • Net income attributable to HUTCHMED: $15.9M ($0.02/share basic EPS vs $0.53 in H1 2025, which included $416.3M SHPL gain)
  • Cash & short-term investments: $1.37B as of June 30, 2026
  • ELUNATE in-market sales: +41% to $60.8M; SULANDA: +45% to $18.4M
  • FRUZAQLA ex-US in-market sales: +70% to $68.9M; approved/launched in 41 countries
  • Savolitinib sNDA approved for 3L MET-amplified gastric cancer in China (June 2026)
  • Sovleplenib NDAs accepted with priority review for ITP (Feb 2026) and wAIHA (Apr 2026)
  • Fanregratinib NDA under priority review for 2L FGFR2-driven ICC; pivotal Phase II data showed 42.5% ORR
  • SAFFRON global Phase III (savolitinib) and SANOVO China Phase III topline results expected H2 2026
  • TAZVERIK voluntarily withdrawn by Ipsen in March 2026; $8.9M impairment taken
  • R&D expenses: $78.8M, up 9% from $72.0M, driven by ATTC global clinical programs
  • Full-year 2026 guidance reiterated: Oncology/Immunology revenue $330M-$450M

Financial Impact

Core oncology/immunology revenue growing 13% (10% CER) with strong product momentum; net income down due to prior-year one-time gain; cash position robust at $1.37B; guidance reiterated with midpoint implying H2 pick-up

revenuenet incomecashR&D spendproduct sales

Risk Factors

  • China regulatory and pricing/payer environment remains uncertain; NRDL renewals could pressure margins
  • SAFFRON and SANOVO Phase III trials may miss endpoints, delaying global filings for savolitinib
  • CEO on leave of absence adds management uncertainty
  • TAZVERIK withdrawal signals potential safety or commercial risk in partnered products
  • ATTC platform is early-stage (Phase I) with no clinical proof-of-concept yet
  • RMB appreciation against USD impacted reported results by ~5% in H1 2026; further FX headwinds possible
  • Competition in CRC (FRUZAQLA) and NET (SULANDA) from newer therapies

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-088458
Document: hcm-20260730xex99d2.htm0001104659-26-088458
Document: hcm-20260730x6k.htm0001104659-26-088458
Document: 0001104659-26-088458-index-headers.html0001104659-26-088458
Document: 0001104659-26-088458-index.html0001104659-26-088458
Document: 0001104659-26-088458.txt0001104659-26-088458

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026